Albumin-bilirubin score: Monitoring hepatic function in patients with chronic hepatitis C virus infection

Table 1 Diagnostic performance of the albumin-bilirubin score across liver diseases

Liver disease	Study type	Country	Sample size	Key findings
Chronic HCV fibrosis staging	Retrospective diagnostic accuracy	Japan	382	Cutoff of 2.125; sensitivity of 73.2%; specificity of 87.1%. ALBI differentiated fibrosis stages (F0-F4). Lower scores associated with improved HCC-free and overall survival
Chronic HCV advanced fibrosis/cirrhosis	Cross-sectional diagnostic study	Egypt	781	Area under the receiver operating characteristic of 0.73-0.74; cutoff of 2.95; sensitivity approximately 79%; specificity approximately 53%. Moderate diagnostic performance for F3-F4
HCV cirrhosis portal hypertension and encephalopathy	Retrospective correlation study	United States	61	ALBI score correlated with portal hypertension (P = 0.023) and encephalopathy (P = 0.038)
Nonviral HCC in MASLD/metabolic dysfunction-associated steatohepatitis fibrosis risk assessment	Observational study	Japan	190	Cutoff of 2.60. ALBI showed high omission rates (35.8%-62.6%). Fibrosis-4 and MASLD fibrosis score performed better for high-risk group identification

ALBI: Albumin-bilirubin; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; MASLD: Metabolic dysfunction-associated steatotic liver disease.